NICE to increase use of real-world evidence

  • NICE plans to use more data resources than RCTs this year for submissions
  • MHRA already takes account of real-world studies, in order to facilitate their upcoming 150 day licensing commitments
  • The utilisation of real world data will be key in tackling the funding and access issue surrounding NICE reimbursement

Click here to learn more

About SVMPharma

SVMPharma is an innovative strategic consultancy, specialising in Real World Evidence (RWE) for the pharmaceutical industry. SVMPharma generates RWE within UK and Europe through bespoke online Real World Treatment Evaluators, leading to successful health technology appraisal (HTA) submissions. Clinical trial programmes do not reflect real-world clinical practice and outcomes, RWE supplements and enhances clinical datasets. SVMPharma’s specialist teams focus on delivering the outcomes that matter to your brand.

For more information, please visit and contact us at

ref: FEB2020LN002